ABOUT OSTOMYCURE

OstomyCure AS is a Medical Technology company with HQ in Oslo, Norway. The company has developed a revolutionary technology called Transcutaneous Implant Evacuation Solution, the TIES Solution.

The TIES Continent Ileostomy Solution is a titanium implant solution with lid intended to replace a conventional ileostomy. It allows a more carefree life for patients who suffer from inflammatory bowel diseases such as Crohn’s disease, Ulcerative colitis, cancers or other related diseases that necessitate removal of the colon (large intestine).

  • The TIES Solution is the result of several years of research combined with the latest 3D manufacturing technology. It has been developed and manufactured in accordance with regulatory standards to ensure patient safety.
  • The company was awarded the certification ISO 13485 Quality Management System for Medical Devices in 2011.
  • The TIES System received CE marking according to the Medical Device Directive (MDD) in June 2016. To meet the added requirements under the new European Medical Device Regulation (MDR), an extended clinical study is ongoing to gather more data on performance, usability, quality of life and health economics.
  • OstomyCure addresses a market estimated at USD 2 billion per year.

INVESTOR RELATIONS

  • OstomyCure AS

    is a privately held company financed by private equity and public research grants.

  • In addition to private equity, the company is grateful for extensive support from The Research Council of Norway & Innovation Norway as well as EU Commission FTI Horizon 2020, which has been instrumental in our development.

Shareholders

  • Kistefos AS
  • Canica AS
  • Inven2
  • Others

OSTOMYCURE MANAGEMENT & ADVISORS